Historically, due to several analytical limitations in GH and insulin-like growth factor I (IGF-I) assays, the confirmation of clinically suspected acromegaly was primarily based on dynamic tests involving the administration of substances known to acutely and physiologically modulate GH secretion. This evidence concerns the gene IGF1 and acromegaly.